Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Keam, Bhumsuk ^a   Im, Seock Ah ^a   Koh, Youngil ^a   Han, Sae Won ^a   Oh, Do Youn ^a   Cho, Nariya ^a   Kim, Jee H ^a   Han, Wonshik ^a   Kang, Keon W ^a   Moon, Woo K ^a   Kim, Tae You ^a   Park, In A ^a   Noh, Dong Young ^a   Chung, June Key ^a   Bang, Yung Jue ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Breast cancer; Fdg pet; Molecular phenotype; Neoadjuvant chemotherapy

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORINE 18; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MASTECTOMY; METABOLISM; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PHENOTYPE; PREDICTIVE VALUE; PROSPECTIVE STUDY; ADJUVANT THERAPY; AGED; BREAST TUMOR; FEMALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; SCINTISCANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TUMOR MARKERS, BIOLOGICAL;

EID: 80054113983     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-452     Document Type: Article

References (40)

1. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, Noh HI, Pisani P, Park JG. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat 2005, 37:325-331. 10.4143/crt.2005.37.6.325, 2785938, 19956367.
2. Esteva FJ, Hortobagyi GN. Locally advanced breast cancer. Hematol Oncol Clin North Am 1999, 13:457-472. vii, 10.1016/S0889-8588(05)70065-4, 10363140.
3. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004, 10:3249-3261. 10.1158/1078-0432.CCR-03-0133, 15161677.
4. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003, 21:2600-2608. 10.1200/JCO.2003.01.136, 12829681.
5. Couturier O, Jerusalem G, N'Guyen JM, Hustinx R. Sequential positron emission tomography using [18f]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006, 12:6437-6443. 10.1158/1078-0432.CCR-06-0383, 17085657.
6. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol 2008, 26:712-720. 10.1200/JCO.2007.13.8412, 18258978.
7. Lee JH, Rosen EL, Mankoff DA. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: Part 2--response to therapy, other indications, and future directions. J Nucl Med 2009, 50:738-748. 10.2967/jnumed.108.061416, 19372493.
8. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of fdg-pet in the axillary staging of breast cancer. Med Sci Monit 2007, 13:RA37-46.
9. Emmering J, Krak NC, Van der Hoeven JJ, Spreeuwenberg MD, Twisk JW, Meijer S, Pinedo HM, Hoekstra OS. Preoperative [18f] fdg-pet after chemotherapy in locally advanced breast cancer: Prognostic value as compared with histopathology. Ann Oncol 2008, 19:1573-1577. 10.1093/annonc/mdn185, 18552360.
10. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18f]fdg pet for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004, 15:1352-1357. 10.1093/annonc/mdh345, 15319241.
11. Krak NC, Hoekstra OS, Lammertsma AA. Measuring response to chemotherapy in locally advanced breast cancer: Methodological considerations. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S103-111.
12. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M. Monitoring of early response to neoadjuvant chemotherapy in stage ii and iii breast cancer by [18f]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006, 24:5366-5372. 10.1200/JCO.2006.05.7406, 17088570.
13. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, Schwaiger M. Positron emission tomography using [(18)f]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000, 18:1689-1695.
14. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2009, 116:153-160. 10.1007/s10549-008-0160-9, 18787948.
15. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Prognostic impact of clinicopathologic parameters in stage ii/iii breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: Paradoxical features of the triple negative breast cancer. BMC Cancer 2007, 7:203. 10.1186/1471-2407-7-203, 2217558, 17976237.
16. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002, 20:379-387. 10.1200/JCO.20.2.379, 11786564.
17. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011, 47:2084-2090. 10.1016/j.ejca.2011.06.014, 21737257.
18. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
20. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, Sledge GW, Whelan TJ, Pfister DG. Postmastectomy radiotherapy: Clinical practice guidelines of the american society of clinical oncology. J Clin Oncol 2001, 19:1539-1569.
21. Han S, Kim SB, Kang SS, Noh WC, Paik NS, Chang ES, Kim JR, Lim SH, Park HS. A phase ii study of neoadjuvant docetaxel plus doxorubicin (kbcs-01) in stage ii, iii breast cancer. Breast Cancer Res Treat 2006, 98:57-61. 10.1007/s10549-005-9131-6, 16752226.
22. Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Prognostic significance of bcl-2 expression in stage iii breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2007, 7:63. 10.1186/1471-2407-7-63, 1863427, 17430582.
23. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. Her2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002, 77:148-154. 10.4065/77.2.148, 11838648.
24. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334. 10.1158/1078-0432.CCR-06-1109, 17438091.
25. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998, 77:621-626. 10.1038/bjc.1998.99, 2149927, 9484820.
26. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007, 25:2650-2655. 10.1200/JCO.2006.08.2271, 17602071.
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10. 10.1016/0197-2456(89)90015-9, 2702835.
28. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. J Clin Oncol 2000, 18:3495-3502.
29. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, Mehta SN. The role of (18)f-fdg pet/ct in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009,
30. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F. [18f]fdg-pet predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007, 34:1915-1924. 10.1007/s00259-007-0459-5, 17579854.
31. Duch J, Fuster D, Munoz M, Fernandez PL, Paredes P, Fontanillas M, Guzman F, Rubi S, Lomena FJ, Pons F. (18)f-fdg pet/ct for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009,
32. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008, 26:4449-4457. 10.1200/JCO.2007.15.4385, 2653115, 18626006.
33. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003, 44:1806-1814.
34. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI, Smith TA, Hutcheon AW, Miller ID, Smith IC, Heys SD. Monitoring primary breast cancer throughout chemotherapy using fdg-pet. Breast Cancer Res Treat 2007, 102:75-84. 10.1007/s10549-006-9316-7, 16897427.
35. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18f]fluorodeoxyglucose. J Clin Oncol 2009, 27:535-541.
36. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF. Positron emission tomography using [(18)f]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000, 18:1676-1688.
37. Jung SY, Kim SK, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Park IH, Lee KS, Shin KH, Lee S, Kim SW, Kang HS, Ro J. Prognostic impact of [(18)f] fdg-pet in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2009,
38. Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, Nathrath W, Schwaiger M. Glucose metabolism of breast cancer assessed by 18f-fdg pet: Histologic and immunohistochemical tissue analysis. J Nucl Med 2001, 42:9-16.
39. Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, Moon HG, Park IA, Oh DY, Im SA, Kim TY, Hwang KT, Kim SW, Noh DY. Ki-67 expression gives additional prognostic information on st. Gallen 2007 and adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009,
40. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/her2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: A potentially useful method for disease characterization. Cancer 2008, 112:995-1000. 10.1002/cncr.23226, 18098228.